Molecular mass: 570.646 g/mol PubChem compound: 54732242
Naldemedine is an antagonist of opioid binding at the mu-, delta-, and kappa-opioid receptors. Naldemedine functions as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids without reversing the central nervous system (CNS)-mediated opioid effects.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A06AH05 | A Alimentary tract and metabolism → A06 Laxatives → A06A Laxatives → A06AH Peripheral opioid receptor antagonists | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| RIZMOIC Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Naldemedine is an active ingredient of these brands:
United States (US)
Austria (AT)
Croatia (HR)
Estonia (EE)
France (FR)
Ireland (IE)
Italy (IT)
Japan (JP)
Lithuania (LT)
Poland (PL)
Spain (ES)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
